HLA-G, HLA-E, and IDO overexpression predicts a worse survival of Tunisian patients with vulvar squamous cell carcinoma.
Adult
Aged
Aged, 80 and over
Biomarkers, Tumor
/ metabolism
Carcinoma, Squamous Cell
/ metabolism
Case-Control Studies
Female
Follow-Up Studies
HLA-G Antigens
/ metabolism
Histocompatibility Antigens Class I
/ metabolism
Humans
Indoleamine-Pyrrole 2,3,-Dioxygenase
/ metabolism
Middle Aged
Neoplasm Invasiveness
Prognosis
Survival Rate
Vulvar Neoplasms
/ metabolism
HLA-E Antigens
HLA-E
HLA-G
IDO
prognostic
survival
vulvar cancer
Journal
HLA
ISSN: 2059-2310
Titre abrégé: HLA
Pays: England
ID NLM: 101675570
Informations de publication
Date de publication:
07 2019
07 2019
Historique:
received:
22
12
2018
revised:
19
03
2019
accepted:
21
03
2019
pubmed:
25
3
2019
medline:
22
5
2020
entrez:
26
3
2019
Statut:
ppublish
Résumé
Little is known about non-classical HLA molecules in vulvar squamous cell carcinoma (VSCC). Because of the indoleamine-2,3-dioxygenase (IDO) immune tolerant role in association with HLA-G, we evaluated the clinical and prognostic value of HLA-G, HLA-E, and IDO in VSCC. HLA-G, HLA-E, and IDO expression was determined by immunohistochemistry in VSCC and associated with clinicopathological parameters and disease outcome. These three molecules were highly represented in tumoral tissues vs healthy matched vulvar tissues (P = 0.0001). Significant differences in HLA-G expression in stages, tumor size, tumor invasion depth, and resection margins subgroups were reported (P < 0.05). At 5 years, the cumulative survival rates was of 79.8% in patients with HLA-G
Substances chimiques
Biomarkers, Tumor
0
HLA-G Antigens
0
Histocompatibility Antigens Class I
0
Indoleamine-Pyrrole 2,3,-Dioxygenase
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
11-24Subventions
Organisme : Ministry of Higher Education and Scientific Research
Pays : International
Informations de copyright
© 2019 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.